FDA Approves Dupilumab for Children With Eosinophilic Esophagitis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 29, 2024.

By Lori Solomon HealthDay Reporter

MONDAY, Jan. 29, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of pediatric patients (aged 1 to 11 years) with eosinophilic esophagitis (EoE).

This approval, for children weighing at least 15 kg, expands the May 2022 FDA approval for patients with EoE aged 12 years and older weighing at least 40 kg.

The approval is based on data from the phase 3 EoE KIDS trial with two parts (part A and B). The study revealed that at 16 weeks, 66 percent of children who received higher-dose Dupixent at tiered dosing regimens based on weight achieved histological disease remission (no more than six eosinophils/high power field), the primary end point, versus 3 percent receiving placebo. At week 52, histological remission was sustained for 17 of 32 children (53 percent) receiving Dupixent in parts A and B; histological remission was also achieved in eight of 15 children (53 percent) who switched to Dupixent from placebo in part B. At week 16, based on caregiver reports, a greater decrease in the proportion of days with one or more signs of EoE was seen in children treated with Dupixent versus placebo.

"With this approval, Dupixent becomes the first and only treatment option for EoE patients aged 1 and older, weighing at least 15 kg," George D. Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron and a principal inventor of Dupixent, said in a statement. "By targeting the underlying type 2 inflammation that contributes to this disease, Dupixent has the potential to transform the standard of care for these children as it has for adults and adolescents with EoE."

Approval of Dupixent was granted to Regeneron.

Press Release

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-01-30 08:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords